Total Payments
$188,579
2024 Payments
$993.57
Companies
28
Transactions
278
Medicare Patients
2,503
Medicare Billing
$300,552
Payment Breakdown by Category
Research$183,761 (97.4%)
Food & Beverage$4,271 (2.3%)
Travel$529.68 (0.3%)
Education$17.32 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $183,761 | 7 | 97.4% |
| Food and Beverage | $4,271 | 268 | 2.3% |
| Travel and Lodging | $529.68 | 2 | 0.3% |
| Education | $17.32 | 1 | 0.0% |
Payments by Type
Research
$183,761
7 transactions
General
$4,818
271 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celltrion, Inc. | $173,841 | 5 | $0 (2023) |
| Eli Lilly and Company | $9,920 | 2 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,300 | 91 | $0 (2024) |
| Abbott Laboratories | $529.68 | 2 | $0 (2024) |
| ABBVIE INC. | $529.67 | 30 | $0 (2024) |
| Allergan Inc. | $395.67 | 35 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $348.85 | 18 | $0 (2023) |
| Janssen Biotech, Inc. | $293.78 | 16 | $0 (2024) |
| Romark Laboratories, LC | $227.68 | 13 | $0 (2020) |
| NESTLE HEALTHCARE NUTRITION INC. | $143.70 | 8 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $993.57 | 27 | Abbott Laboratories ($529.68) |
| 2023 | $1,619 | 15 | Eli Lilly and Company ($859.89) |
| 2022 | $17,235 | 33 | Celltrion, Inc. ($16,695) |
| 2021 | $78,208 | 51 | Celltrion, Inc. ($68,342) |
| 2020 | $70,714 | 44 | Celltrion, Inc. ($70,004) |
| 2019 | $19,078 | 58 | Celltrion, Inc. ($18,300) |
| 2018 | $370.03 | 29 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($129.04) |
| 2017 | $360.69 | 21 | Allergan Inc. ($122.71) |
All Payment Transactions
278 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $9.63 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/12/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 11/05/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/31/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Travel and Lodging | In-kind items and services | $520.66 | General |
| Category: Heart Failure | ||||||
| 10/31/2024 | Abbott Laboratories | CARDIOMEMS (Device) | Travel and Lodging | In-kind items and services | $9.02 | General |
| Category: Heart Failure | ||||||
| 10/18/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.44 | General |
| Category: Immunology | ||||||
| 10/03/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $20.35 | General |
| Category: Immunology | ||||||
| 10/01/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $29.79 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 09/26/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: Gastroenterology | ||||||
| 09/24/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: ONCOLOGY | ||||||
| 09/12/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: Gastroenterology | ||||||
| 08/15/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $30.10 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/05/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $15.87 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 07/02/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $22.81 | General |
| Category: IMMUNOLOGY | ||||||
| 06/24/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $18.28 | General |
| Category: Neuroscience | ||||||
| 06/17/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $24.89 | General |
| Category: IMMUNOLOGY | ||||||
| 06/03/2024 | Celltrion USA Inc. | ZYMFENTRA (Biological) | Education | In-kind items and services | $17.32 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/29/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $6.99 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 05/20/2024 | ABBVIE INC. | HUMIRA (Biological), RINVOQ, SKYRIZI | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: IMMUNOLOGY | ||||||
| 05/14/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $30.39 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/22/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $18.70 | General |
| Category: Gastroenterology | ||||||
| 04/22/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Immunology | ||||||
| 03/12/2024 | PFIZER INC. | VELSIPITY (Drug) | Food and Beverage | In-kind items and services | $12.89 | General |
| Category: INFLAMMATION;PAIN | ||||||
| 03/04/2024 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $16.08 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CT-P13 3.8 | Celltrion, Inc. | $85,537 | 3 |
| CT-P13 3.7, CT-P13 3.8 | Celltrion, Inc. | $70,004 | 1 |
| Ct-P13 3.8 | Celltrion, Inc. | $18,300 | 1 |
| A PHASE 3B, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO- AND ACTIVE- CONTROLLED TREAT-THROUGH STUDY OF MIRIKIZUMAB AND VEDOLIZUMAB IN PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | Eli Lilly and Company | $9,060 | 1 |
| A MULTICENTER PHASE 3B OPEN-LABEL SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | Eli Lilly and Company | $859.89 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 788 | 1,293 | $408,991 | $94,780 |
| 2022 | 12 | 632 | 991 | $303,477 | $76,072 |
| 2021 | 10 | 521 | 778 | $252,716 | $63,301 |
| 2020 | 11 | 562 | 829 | $284,716 | $66,399 |
Total Patients
2,503
Total Services
3,891
Medicare Billing
$300,552
Procedure Codes
47
All Medicare Procedures & Services
47 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 163 | 295 | $66,375 | $26,965 | 40.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 90 | 91 | $81,263 | $10,718 | 13.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 123 | 123 | $27,675 | $8,841 | 31.9% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2023 | 47 | 123 | $22,632 | $8,570 | 37.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 93 | 293 | $41,020 | $8,179 | 19.9% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2023 | 47 | 122 | $15,494 | $6,887 | 44.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 83 | 84 | $64,764 | $6,637 | 10.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 45 | 46 | $18,354 | $6,130 | 33.4% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 26 | 26 | $26,234 | $4,413 | 16.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 28 | 47 | $6,721 | $2,919 | 43.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 12 | 12 | $10,716 | $2,231 | 20.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 11 | 11 | $9,823 | $2,041 | 20.8% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2023 | 20 | 20 | $17,920 | $250.20 | 1.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 145 | 269 | $59,293 | $25,570 | 43.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 59 | 60 | $23,940 | $9,460 | 39.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 110 | 110 | $24,622 | $7,809 | 31.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 58 | 58 | $51,794 | $6,414 | 12.4% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 64 | 67 | $51,286 | $5,930 | 11.6% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 68 | 214 | $29,960 | $5,559 | 18.6% |
| 88312 | Special stained specimen slides to identify organisms including interpretation and report | Office | 2022 | 22 | 52 | $9,568 | $3,486 | 36.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 34 | 59 | $8,437 | $3,400 | 40.3% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2022 | 23 | 53 | $6,731 | $2,833 | 42.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 11 | 11 | $9,823 | $2,073 | 21.1% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 12 | 12 | $12,108 | $1,948 | 16.1% |
| 45381 | Injection beneath lining of large bowel using a flexible endoscope | Facility | 2022 | 15 | 15 | $13,440 | $909.00 | 6.8% |
About Dr. James Maher, MD
Dr. James Maher, MD is a Gastroenterology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1497743165.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Maher, MD has received a total of $188,579 in payments from pharmaceutical and medical device companies, with $993.57 received in 2024. These payments were reported across 278 transactions from 28 companies. The most common payment nature is "" ($183,761).
As a Medicare-enrolled provider, Maher has provided services to 2,503 Medicare beneficiaries, totaling 3,891 services with total Medicare billing of $300,552. Data is available for 4 years (2020–2023), covering 47 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Houston, TX
- Active Since 10/07/2005
- Last Updated 02/09/2015
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1497743165
Products in Payments
- XIFAXAN (Drug) $824.98
- CARDIOMEMS (Device) $529.68
- TRULANCE (Drug) $353.39
- LINZESS (Drug) $325.94
- STELARA (Biological) $243.58
- ENTYVIO (Biological) $227.91
- ZENPEP (Drug) $173.07
- ZEPOSIA (Drug) $142.54
- Creon (Drug) $139.32
- MAVYRET (Drug) $132.50
- Talicia (Drug) $114.81
- ALINIA (Drug) $100.47
- SUTAB (Drug) $98.48
- VELSIPITY (Drug) $90.51
- Trulance (Drug) $84.27
- DUPIXENT (Biological) $75.44
- VOQUEZNA (Drug) $73.91
- VIBERZI (Drug) $70.11
- Entyvio (Biological) $68.73
- Alinia Tablets 500mg 30 count bottle (Drug) $67.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Houston
Dr. Bincy Abraham, Md, MD
Gastroenterology — Payments: $1.9M
Gastroenterology $1.9M
Dr. Isaac Raijman, Md, MD
Gastroenterology — Payments: $1.6M
Gastroenterology $1.6M
Dr. Brooks Cash, Md, MD
Gastroenterology — Payments: $1.3M
Gastroenterology $1.3M
Dr. Mazen Noureddin, M.d, M.D
Gastroenterology — Payments: $786,099
Gastroenterology $786,099
Dr. Jason Hou, M.d, M.D
Gastroenterology — Payments: $372,514
Gastroenterology $372,514
Kalpesh Patel, Md, MD
Gastroenterology — Payments: $313,187
Gastroenterology $313,187